Floatz logo

Docetaxel

Prostate Adenocarcinoma

Instituto do Cancer do Estado de São PauloSmall moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

88 Active assets in the Prostate Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Nilutamide
SWOG Cancer Research Network
Phase 3BB
Degarelix
Canadian Cancer Trials Group
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2BB
Prednisone
Mayo Clinic
Phase 3BB
Goserelin
CancerCare Manitoba
Phase 3BB

View all 50 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmActive
BBB
Indicative · Phase 4
73 / 100
View asset →
pancreatic adenocarcinomaActive
BBB
Indicative · Phase 2
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative · Phase 2
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →